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Abstract: Autophagy is involved in different degenerative diseases and it may control epigenetic
modifications, metabolic processes, stem cells differentiation as well as apoptosis. Autophagy plays
a key role in maintaining the homeostasis of cartilage, the tissue produced by chondrocytes; its
impairment has been associated to cartilage dysfunctions such as osteoarthritis (OA). Due to their
location in a reduced oxygen context, both differentiating and mature chondrocytes are at risk of
premature apoptosis, which can be prevented by autophagy. AutophagomiRNAs, which regulate the
autophagic process, have been found differentially expressed in OA. AutophagomiRNAs, as well as
other regulatory molecules, may also be useful as therapeutic targets. In this review, we describe and
discuss the role of autophagy in OA, focusing mainly on the control of autophagomiRNAs in OA
pathogenesis and their potential therapeutic applications.
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1. Background
Chondrogenesis, the process by which cartilage is formed, occurs as a result of mes-
enchymal cell condensation and chondroprogenitor cell differentiation. SOX9 is the master
transcription factor for MSCs differentiation into chondrocytes [1]. During development,
chondrogenesis is subject to complex regulation by several interplaying factors such as
fibroblast growth factor (FGF), transforming growth factor β (TGFβ), bone morphogenetic
proteins (BMPs) and Wnt signaling pathways. Among regulatory factors, TGFβ plays a key
role in development. TGFβ receptors are present in many cells, and an integrin-applied
force is required to release TGF-β from its prodomain. Force application has been shown
to occurs through the prodomain of TGF-β and through the β subunit of the integrin [2].
In the process termed endochondral ossification, chondrocytes undergo proliferation and
terminal differentiation to hypertrophy and apoptosis, whereby hypertrophic cartilage is
replaced by bone tissue. In mature articular cartilage, instead, chondrocytes are respon-
sible for the production and homeostatic maintenance of the extracellular matrix (ECM)
components.
Structural ECM components are: collagens (mainly type II collagen), proteoglycans,
(including aggrecan, decorin, biglycan and fibromodulin) and noncollagenous proteins,
such as cartilage oligomeric protein (COMP), cartilage matrix protein (CMP) and fibronectin.
The primary matrix degrading enzymes involved in cartilage turnover are metallopro-
teinases (MMPs) and cathepsins (CTS). In healthy articular cartilage, balanced degradation
and synthesis by chondrocytes ensure tissue homeostasis.
Autophagy plays a key role in the preservation of cartilage integrity [3]. Besides
playing a crucial role in adaptive response to different stimuli, it is also required for
intracellular quality control and is involved in removing and recycling misfolded proteins,
damaged organelles or dysfunctional cell components [4].
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Authophagy may be distinguished into (i) macroautophagy; (ii) microautophagy; (iii)
chaperone mediated autophagy. Macroautophagy represents the prevalent form of au-
tophagy in different cell types. It starts with a membrane formation, the phagophore, which
expands to engulf the cellular cargo, generating the autophagosome. This latter structure
matures through fusion with lysosomes. mTOR is a major player in autophagy and acts
as a signaling control point downstream of growth factor receptor signaling, hypoxia,
ATP levels and insulin signaling. It is activated downstream of Akt kinase, PI3-kinase
and growth factor receptor and acts to inhibit autophagy by modulating the Ulk1 (Atg1)
complex. In response to the autophagy cascade activation, the IIIPI3K complex produces
PI3P and induces other Atg proteins, such as the Atg12-Atg5-Atg-16 and LC3 (Atg8)-
phosphatidylethanolamine complexes. After translation, proLC3 is proteolytically cleaved
generating LC3-I. Upon induction of autophagy, LC3-I is conjugated by the Atg7, Atg3
and Atg12-Atg5-Atg16L complexes to the highly lipophilic phosphatidylethanolamine (PE)
moiety to generate LC3-II. Finally, PE promotes integration of LC3-II into lipid membranes
allowing autophagosomes formation. Due to its crucial role as a natural defense mecha-
nism against inflammatory, infectious and degenerative disorders, the autophagic process
must be tightly regulated. Several molecular mechanisms of autophagy regulation have
been investigated: microRNAs (miRNAs) stand out, among others [5]. These small non-
coding RNAs act as negative regulators of specific target mRNAs expression. One single
miRNA can act as a post-transcriptional repressor by binding to partially complementary
sequences in the 3′UTR sites of various mRNAs. miRNAs which regulate the autophagic
process, predominantly targeting the pathway early stages, are called autophagomiRNAs.
In several pathological conditions, e.g., degenerative disorders, autophagomiRNAs have
been found to be differentially expressed [6].
Increasing evidence suggests that autophagy dysregulation is closely related to the
pathogenesis of osteoarthritis (OA) [7] (Figure 1).
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Figure 1. Schematic representation showing changes occurring in the autophagic process in normal versus osteoarthritic
chondrocytes.
OA, a chronic, age-related degenerative disease of articular cartilage, is associated
with dramatic changes in cartilage homeostasis, due to an imbalance between degradation
and synthesis by chondrocytes. Age-related changes that occur in joints are thought to
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represent a major risk factor for OA development. OA may develop in any joint, but most
commonly, it affects the knee, hip, hand, spine and foot.
Incidence is higher in women than in men, especially beyond age 50. Worldwide
estimates indicate that 10% of men and 18% of women ≥ 60 years have symptomatic OA.
Disease progression is usually slow but can ultimately lead to joint failure with pain and
disability, with considerable socio-economic impact [8].
2. Role of the Autophagic Process in Chondrogenic Differentiation
Autophagy is involved in different cellular processes such as the control of epigenetic
modifications, metabolic processes, cellular senescence and apoptosis, as well as stem cells
differentiation steps [9]. Recent studies have demonstrated that the autophagic process is
crucial for stem cell functioning [10,11]. Mesenchymal stem cells have trilineage potency
(adipocyte, osteoblast and chondrocyte); they are essential for homeostasis maintenance
and tissues repair. Chondrogenesis is a dynamic process associated with morphological
changes and metabolic stress [12]. Healthy chondrocytes are essential for a functional carti-
lage, but their regenerative potential is very limited; hence, both chondrocytic homeostasis
and cartilage extracellular matrix integrity are required [11]. Endochondral ossification,
a process where chondrocytes differentiate to form the growth plate, is essential in mam-
malian bone formation. As the growth plate is poorly vascularized, chondrocytes grow
in an hypoxic environment [13]. In such a context, autophagy is induced, preventing
premature apoptosis of differentiating and mature chondrocytes. In fact, the chondrocytic
maturation phase is regulated by mTOR and AMP kinase (AMPK) activity [14]. AMPK, a
molecule involved in the regulation of cellular metabolism, acts by inducing autophagy,
whereas mTOR, a regulator of cell growth, inhibits autophagy [15]. AMPK and mTORC
(complex1 of mTOR) provide an integrated signal by phosphorylating ULK 1 protein
kinase in a coordinated way so that the cells are able to respond appropriately to external
factors [15]. During endochondral ossification, chondrocytes produce extracellular matrix
components: the endoplasmic reticulum (ER), involved in the secretory process, is in a
stressful condition. Consequently, ER stress induces autophagy in order to maintain its
homeostasis [16]. Recently, it has been demonstrated that a faulty autophagic process
induces ER stress and affects chondrogenesis [8]. Under mechanical stimuli, such as com-
pression, autophagy preserves intervertebral disc degeneration. However, a persistent
compression stimulus can induce excessive autophagy leading to cellular apoptosis [17].
Ma et al. demonstrated that autophagy is mediated by ROS (reactive oxygen species) in
nucleus pulposus cells of rats exposed to compressive stimuli [18]. The levels of reactive
oxygen and nitrogen species (RONS) induced by IL-1 can be influenced by oxygen tension.
Indeed, environmental oxygen tension in articular chondrocytes has been shown to play
an important role in determining their ability to counteract RONS exposure in OA [19]. In
addition, we have demonstrated increased expression during physical activity of chondro-
genic transcription factors SOX9 in circulating mesenchymal progenitors associated with
autophagy [20]. This finding suggests the beneficial role of physical exercise in preserving
chondrogenesis. Autophagy adjusts mitochondrial activity in stem cells in order to pro-
vide the best metabolic conditions, thus limiting ROS production, preventing metabolic
stress and genome damage. Mitochondria, as cellular energy producers, are involved in
many vital processes [21]. Mitochondria dysfunctions cause cellular damages in many
aging-related diseases such as osteoarthritis [22]. Maintenance of a correct mitochondrial
functionality appears therefore very important. Mitophagy, the autophagy process involv-
ing damaged mitochondria, contributes to a correct mitochondrial activity [23]. Different
mitophagy mechanisms as well as different mitophagy inducers have been investigated.
Generally, mitophagy can be PRKN (parkin RBR E3 ubiquitin protein ligase)-dependent or
PRKN-independent [24]. In animal models, it has been demonstrated that the chondrogenic
commitment involves LC3-Dependent Mitophagy [25] and that mitophagy improves the
chondrogenic differentiation potential of Adipose Stem Cells [26]. Additionally, mitophagy
regulators such as PINK1, PRKN, BNIP3 and MFN2 were shown to be involved in OA
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pathogenesis [24]. In particular, the PINK1-PRKN pathway plays an important role in the
induction of mitophagy in chondrocytes [24]. Therefore, mitophagy appears as an effective
contrast tool against OA development.
3. MicroRNAs Involvement in the Autophagy Process
Autophagy dysfunctions are involved in cartilage deterioration, whereas induction
of autophagy can counteract cartilage degeneration. ULK1, LC3 and beclin, autophagy-
related proteins, are expressed in cartilage. However, their expression is reduced in OA
disorder [27]. In addition, the expression of LC3, ULK-1, P62 and Beclin-1 in chondrocytes is
downregulated by miR-411 [28]. Recently, it has been demonstrated that miR-375 worsens
knee osteoarthritis by targeting the autophagy related protein ATG2B [29]. Reduced
circulating miR let-7e levels are associated to increased apoptosis and reduced autophagy
in knee OA cartilage [30]. Undoubtedly, miRNAs play a crucial role in cartilage homeostasis
as well as in the autophagic process. In particular, level changes in miRNAs targeting the
autophagic pathway (autophagomiRNAs) may influence the development of OA [31].
MiRNAs may be recovered from biological samples such as plasma, serum, cartilage
and synovial fluid, as they are secreted from cells in exosomes or encapsulated within
microvesicles. Quantification and analysis of several autophagomiRNAs reveal differen-
tial expression levels in samples from OA patients, compared with healthy controls [4].
Panels of cartilage miRNAs, which appear deregulated in OA, have been proposed as
diagnostic/prognostic markers. A sample of those cited in this review is shown in Figure 2.
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Figure 2. Schematic representation of changes that occur in a healthy knee joint (I) upon OA degenerative process (II): (a)
osteophytes production; (b) cartilage thinning; (c) cartilage fragmentation. (III) The table reports a few miRNAs cited
within the text, which are differentially expressed in OA cartilage, compared to healthy cartilage. ↑ = enhanced expression;
↓ = lowered expression.
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4. Transcription Factors in OA
Transcription factors are DNA-binding proteins which play a central role in regulating
gene expression [32] and, consequently, are involved in cell signaling as well as in cellular
proliferation and differentiation [33].
Some transcription factors, defined Master regulators, commit progenitor cells differ-
entiation by inducing the expression of lineage-specific genes [34]. Generally, transcription
factors recognize highly conserved sequences (6 to 12 bp long) upstream target genes [35].
Notably, the same transcription factors can differently modulate gene expression on the
basis of specific interactions [36]. Furthermore, posttranslational modifications, such as
phosphorylation/dephosphorylation, may regulate transcription factors efficiency [37].
Transcription factor SOX9 is the master regulator of chondrogenic differentiation. It acts
by inducing mesenchymal cells condensation and proliferation and inhibits chondrocyte
senescence [38]. Cartilage is absent in Sox9-knockout murine embryonic stem cells; human
SOX9 haploinsufficiency induces lethal skeletal malformations [39].
The expression of SOX9 is reduced in chondrocytes of OA patients [40]. In cartilage, it
has been shown that SOX9 regulates miR-140 levels in zebrafish and mammalian cells [41],
while miR-1247 as well as MiR-30a and miR-145 target SOX9 [42–44].
By performing an enrichment analysis, it has been observed that transcription factors,
such as activator protein 1 (AP-1), CCAAT-enhancer-binding protein (C/EBP) and the
activator of transcription 3 (STAT3), may be involved in the regulation of genes whose
expression is altered in OA [45]. A transcriptome study showed altered expression of
transcription factors such as JUN, EGR1, JUND, FOSL2, MYC, KLF4, RelA and FOXO in
the cartilage of OA human knee [46].
The transcription factors AP-1, runt-related transcription factor 2 (RUNX2), NFkB,
HIF2 α and T-cell factor/lymphoid enhancer factor (TCF/LEF) regulate the cartilage
ECM-degrading molecules MMP3 and MMP13 (collagenases), whereas ADAMTS4 and
ADAMTS5 (aggrecanases) are regulated by the transcription factors NFAT, RUNX2, SOX4,
SOX11 and NFkB [47,48]. Interestingly, during chondrogenesis in human adipose-derived
stem cells (hADSCs), it has been demonstrated that miR-193b, miR-199a-3p/has-miR-199b-
3p, miR-455-3p, miR-210, miR-381 and miR-92a target RUNX2 [49].
The upregulation of SOX4 and SOX11 in mouse cartilage is associated to impaired
cartilage and increased expression of ADAMTS5 and MMP13 [48]; chondrocyte proteins
ACAN and COL2A1 are regulated by the transcription factors SOX5, SOX6 and SOX9 [50].
During cartilage formation, miR-193b targets SOX4 and miR-455-3p targets SOX-4, SOX5,
SOX6 and SOX9 [49].
Transcription factor EB (TFEB) and the zinc-finger protein with KRAB and SCAN do-
mains 3 (ZKSCAN3) are important master regulators of autophagy. TFEB, known to induce
autophagy in HeLa cells [51], is reduced in a OA mouse model and in OA human knee
cartilage [52]. On the contrary, ZKSCAN3 inhibits autophagy by blocking the expression of
ULK1 and LC3 genes [53]. ZKSCAN3 expression has not been evaluated in chondrocytes;
however, it has been demonstrated that ZKSCAN3 knockout induces premature aging in
Mesenchymal Stem Cells [54]. SIRT1, whose levels are increased in early chondrocytes but
are reduced in severe OA, promotes autophagy by acting on FOXO family transcription
factors [55]. FOXO1 and FOXO3 induce autophagy [56]. In fact, ATG genes expression is re-
duced in chondrocytes under oxidative stress conditions due to FOXO1 or FOXO1/FOXO3
knockdown [57], while a constitutively expressed mutant FOXO1 increased the expression
of LC3 and Beclin in normal chondrocytes [58]. Interestingly, in osteoarthritis samples,
transcription factors FOXO are reduced [46] and the activated serine/threonine kinase AKT,
which phosphorylates the FOXO transcription factors, is higher in OA cartilage compared
to normal cartilage [59]. By performing in silico analysis and also in vitro and in vivo
experiments, it has been demonstrated that during skeletogenesis FOXO1 is targeted by
miR-182 [60]; bioinformatic analysis has shown that miR182 plays a critical role in OA [61].
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5. In Vitro and In Vivo Models for OA Studies
Different models have been employed to investigate OA pathogenesis. In vitro sys-
tems have been established by using human or murine primary cultures and cell lines.
Usually, a mechanical load or inflammatory cytokines are applied to cells in order to
mimic OA conditions. In particular, OA mimic conditions are applied to cells growing
in a monolayer, in a scaffold or in a co-culture system [62]. The use of 3D cell models
may represent a good alternative to 2D cultures. 3D models for the in vitro analysis of
subchondral bone and articular cartilage currently exist in a variety of forms, including
explants and scaffold-based or scaffold-free systems, each of which has its own advantages
and disadvantages. 3D systems make it possible to observe the various cellular interactions
and to evaluate any changes due to the addition of therapeutic molecules [63]. However,
investigations of explanted tissues allow assessment of the extracellular matrix and cellular
interactions to recapitulate in vivo alterations [64].
In vivo models provide the possibility to evaluate pain, cartilage degeneration and
the bone remodeling process. OA in animal models can be induced or spontaneous.
In particular, OA can be induced surgically or chemically; induced models can also be
generated genetically [65]. Animal models with naturally occurring OA, such as aged
animals, can also be used.
Usual animal models for OA are: mouse, rat, Syrian hamster, rabbit, horse and also cat
and dog [65]. Zebrafish has also been employed for the study of OA. The zebrafish model,
due to its ease of being genetically manipulated and its rapid development, appears to be
very useful. For example, a COL10A1 knockout zebrafish model has been generated for
the study of OA [66].
In fact, the craniofacial cartilage of zebrafish larvae is as mechanically sensitive as
the human one [67]. Different models for the zebrafish jaw development are available,
including wild-type fish [68] and mutants [68]. In addition, zebrafish larvae in different
gravitational fields have been used [68]. The zebrafish model is also suitable for studying
miR-mediated joint degeneration. In particular, zebrafish dicer1 mutant shows impaired
craniofacial development and overexpression of SOX10 [69]. SOX9 controls miR140 and
miR-29; miR92a regulates BMP signaling in zebrafish cartilage [41,70].
The introduction of the CRISPR/Cas9 technology in recent years has further expanded
the possibilities of originating cellular and animal models to study the role of different
genes and regulatory factors involved in degeneration, regeneration and inflammatory
processes associated with OA. The CRISPR/Cas9 system in fact not only allows to knock
out specific genes and functions, but by using modified versions of the Cas9 enzyme, it
becomes possible to originate recombinant proteins that can act as transcriptional activators
and repressors, as well as epigenetic modulators [71], to study in a more precise way the
regulation of specific genes [72]. The possibility to originate new cellular and animal
models [73,74] will be very helpful to overcome the limited availability of animal models
of the disease. In addition, the availability of different models will make drug screening
aimed at identifying new therapies much more efficient, as will the possibility of studying
new therapeutic approaches based on gene therapy [75].
Various treatments have been developed to counteract or, at least delay, OA clinical pro-
gression. Anti-inflammatory drugs are employed, as well as non-pharmacological treatments,
such as electromagnetic stimulation, shock wave therapy and biomechanical intervention [76].
Surgical treatment (e.g., total joint replacement) is chosen for advanced OA.
6. Therapeutic Targets in OA
6.1. Autophagy
Considering its prominent role in cell pathophysiology, autophagy can be therapeu-
tically targeted and modulated at various points of its pathways in human diseases [77].
Preventing autophagy inhibition and decreasing ROS production are strategies with ther-
apeutic potential against OA. mTOR, a signaling molecule in the autophagy pathway,
has been chosen as a target in experimental studies. Rapamycin, an mTOR inhibitor, has
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been proven to delay cartilage degeneration upon intra-articular injection in a murine OA
model [78]. Isoimperatorin and glucosamine can ameliorate osteoarthritis by activating
autophagy and inhibiting mTOR pathway [79]. Resveratrol (RSV) can activate Sirtuin 1
(SIRT1), an autophagy promoter, thus inhibiting OA progression [80].
6.2. Inflammation
The existence of an important inflammatory component in OA is well known. Damage-
associated molecular patterns (DAMPs) and various sources of oxidative stress contribute
to inflammation [81]. An in vitro screening for DMOADs (disease-modifying osteoarthri-
tis drugs) revealed the strong chondrogenic/chondroprotective effects of BNTA (N-[2
bromo-4-phenylsulfonyl-3-thienyl]-2-chlorobenzamide) [82]. BNTA beneficial effects may
be ascribed to its induction of SOD3 expression and superoxide anions elimination. Resver-
atrol (RSV), already cited, is a powerful antioxidant as well.
The condroprotective role of Resveratrol (RSV) may also be associated to its ability
to inhibit inflammation and the NF-κB signaling pathway. The activation of transcription
factor NF-kB, an essential mediator of inflammatory responses, depends on the inducible
degradation of its inhibitor, IkBα [83]. In an in vitro model (IL-β1 treated human chondro-
cytes), the inflammatory response was significantly inhibited by RSV administration [84].
Molecular evidence demonstrated that RSV relieved the inflammatory response by inhibit-
ing IkBα degradation. It is worth recalling that baseline NF-kB activity plays a positive
role in healthy cartilage, ensuring chondrocytes differentiation and survival. Environmen-
tal and inflammatory cues exacerbate NF-κB response, which leads to the expression of
matrix metalloproteinases (MMPs), cyclooxygenases (COX) and inflammatory cytokines
(e.g., IL-1, IL-6, IL-8 and TNF). The MMPs family includes several members, which are
secreted as inactive pro-forms. Once the pro-domain is cleaved, the active enzymes pro-
ceed to ECM proteins degradation. They are involved in physiological processes, such
as embryonic development and tissue remodeling and are overexpressed in degenerative
processes such as OA. MMP13, also called collagenase 3, is a major enzyme targeting
cartilage for degradation. It targets type II collagen, but it also degrades proteoglycans,
type IV and type IX collagen, osteonectin and perlecan. MMP13 overexpression is typically
observed in OA patients [85,86]. The ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) family of aggrecanases also contributes to proteoglycan/aggrecan
depletion. ADAMTS 4 and 5 have been identified as the main aggrecanases involved in OA
development [87]. The above-mentioned catabolic enzymes play an important role in OA
progression, and therefore, represent interesting therapeutic targets for articular cartilage
degradation slowdown [88–91].
6.3. Cell Senescence
Cell senescence is a stress-activated molecular program that prevents damaged cells
from further proliferation. Autophagy and cellular senescence share several stimuli (e.g.,
damaged organelles or macromolecules, oxidative stress). Although autophagy is generally
considered to suppress cellular senescence, various studies have suggested that it may also
promote it [92,93]. Senescent cells (SC) accumulate in chronic age-associated diseases, such
as OA. Their inflammatory senescence-associated secretory phenotype (SASP) severely
damages neighboring cells. SC appear to be resistant to apoptosis due to the upregulation
of pro-survival pathways related to P13K/AKT, p53-p21 and antiapoptotic BCL family
members, among others (Figure 3).
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Table 1. Examples of Senolytics with Their Respective Targets.
Senolytic Drug Targeted Molecules/Pathway
FISETIN ⊥ P13/AKT/mTOR⊥ Bcl2-xL
QUERCETIN ⊥ P13/AKT/mTOR⊥ Bcl2-w
NAVITOCLAX ⊥ Bcl2, Bcl-xL, Bcl-w
FOXO4-DRI ⊗ FOXO4-p53 interaction, no p53 in the nucleus
USP7 inhibitor MDM2 ubiquitination
UBX0101 MDM2, p32
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molecules known to target pro-survival pathways [94]. Molecules meeting these require-
ments are called senolytics, as they selectively induce SC apoptosis [95]. Table 1 reports a
few examples of senolytics and their targets. Targeting is achieved by nanoparticle-based
delivery of senolytics [96].
To our knowledge, there are two current clinical trials in the US involving knee OA
patients treated with senolytic regimens:
• UBX0101(NCT04129944).
• Fisetin (NCT04210986).
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6.4. microRNAs
Other molecular targets for therapeutic options may be specific miRNAs, whose
dysregulation plays an important role in OA. AntagomiRNAs and/or miRNA mimics
may be synthesized and delivered into experimental models in order to remodel microR-
NAs levels. In detail, antagomiRNAs are synthetic oligonucleotides which can inhibit
specific endogenous miRNAs by base-pairing, hence hindering miRNA-target mRNAs
matching. MiRNA mimics instead act in the opposite way: they can be introduced by
transient transfection to enhance the regulatory action of endogenous identical miRNAs.
Their therapeutic effectiveness depends on the actual possibility to deliver them to the
cartilaginous tissue.
OA animal models (mice and rats) have been employed in promising studies so
far. Upregulation of miR21, for example, is associated with OA in humans (Figure 1III)
and it has also been observed in experimental OA murine models [97]. Intra-articular
injection of miR-21 mimics caused a significant worsening of cartilage degradation, whereas
antagomiR-21 injection had the opposite effect. Another experiment on similar OA rat
models [98] demonstrated the therapeutic efficacy of miR-140-5p, an autophagy regulator
(Figure 1III). Rats were treated with intra-articular injection of human umbilical cord stem
cells (hUC-MSCs) ±miR-140-5p mimic. The authors demonstrated that hUC-MSCs+ miR-
140-5p mimic differentiated to chondrocytes and induced rat’s cartilage repair much more
efficiently than hUC-MSCs.
7. Novel Therapeutic Strategies
In addition to the above clinical trials with senolytic molecules, other experimental
treatments are based on the use of miRNAs. An efficient way to deliver therapeutic
miRNAs involves MSC-derived extracellular vesicles (ECVs) [99] ECVs (100–1000 nm
diameter) while exosomes (30–100 nm diameter) are released by several cell types; they
are delimited by phospholipid bilayer membranes and carry various cellular components,
including miRNAs, which—in this way—are protected from degradation. Surface CD
markers allow tracking ECVs’ origin while adhesion molecules facilitate internalization by
recipient cells. Studies conducted on animal models or in in vitro human models (e.g., Il-1β
treated synovial fibroblasts) demonstrated that hMSCs derived exosomes may promote
chondrocytes proliferation and cartilage repair [100,101].
Exosomes may also be exploited as therapeutic agents because of their targeting
capacity and loading ability. By simple incubation, they can be loaded with hydropho-
bic molecules, such as curcumin and other antioxidants, ensuring considerable stability
and bioavailability [102]. Tissue engineering strategies are under development in order
to ensure EVs maintenance within the damaged cartilage [103]. Various scaffold types
have been tested. Among others, hyaluronic acid (HA) and collagen hydrogels seemed
eligible biomaterials for cartilage regeneration. Liu et al. [104] successfully incorporated
EVs obtained from iPSC-MSC into a hydrogel glue, which was then implanted into a
rabbit articular defect model. The evolution of 3D printing technology offers new chances
to exosome-based tissue engineering strategies. Chen et al. tested a 3D printed carti-
lage ECM/gelatin methacrylate (GeMA)/exosome scaffold, which restored chondrocyte
mitochondrial dysfunction and enhanced chondrocyte migration, facilitating cartilage
regeneration in an OA rabbit model. Interestingly, the 3D-printed scaffold could retain
exosomes for 14 days in vitro and for ≥7 days in vivo [105].
Innovative therapeutic approaches based on genome editing using the CRISPR/Cas9
technique are also being evaluated. The technique has a high potential in regenerative
medicine and cell-based applications for cartilage repair [106].
A first therapeutic approach is based on exogenous-cell-based therapy, by delivering
chondrocytes or MSCs previously engineered in vitro. Using this approach, Seidl et al.
reported that by targeting the MMP13 gene, increased accumulation of cartilage matrix
protein type II collagen was achieved using edited cells [107], while the in vitro knockout
of IL1-R1 in chondrocytes before injection reduced inflammation, improving cell-therapy
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results [108]. Other potential therapeutic target genes which have been investigated are
osteocalcin [109] and hyaluronan synthase 2 (HAS2) [110].
An alternative approach relies on intra-articular injection of adeno-associated vi-
ral vectors expressing CRISPR/Cas9 components to target MMP13, IL-1β and NGF;
Zhao et al. [89] reported that the inactivation of these genes may be useful for both pain
management and joint maintenance. Moreover, the Cas9 enzyme may be suitably engi-
neered to originate fusion products with factors such as activators and epigenetic modifiers:
activation or repression of genes involved in inflammation could have an important thera-
peutic potential in OA. Epigenetic editing may also allow programming genes networks to
target stem cell differentiation for their clinical employment for regenerative therapy [111].
Delivery systems involving non-viral vectors may be preferable in order to avoid
inflammatory responses in joints, which can cause adverse side effects [112]. Studies
aimed at evaluating different viral and non-viral vectors for the efficient delivery of the
CRISPR/Cas9 system at the joint level are needed before this new technology can be
proficiently translated into the clinic.
8. Conclusions and Perspectives
As the human lifespan is progressively expanding, the incidence of degenerative
disorders associated with ageing, such as OA, is increasing. Traditional treatment options
for OA aim at relieving symptoms (pain, inflammation) and at delaying severe disability in
patients. Cell-based therapies focusing on the restoration of damaged articular cartilage
have been tested on experimental animal models mimicking the OA phenotype (Figure 4).
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MicroRNAs involved in the regulation of articular cartilage homeostasis, autophagy
and apoptosis show differential expression in OA, i.e., they are either upregulated or down-
regulated in patients compared to healthy controls. MicroRNAs, which can be recovered
from cartilage, blood and synovial fluid, may, therefore, represent diagnostic/prognostic
biomarkers. A special attention has been paid to extracellular vesicles-associated miRNAs:
they represent the most reliable biomarkers, as they are protected from degradation. Most
ECV/exosomes recovered from the OA microenvironment are disease detectors, while
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ECVs/exosomes released by MSCs (cartilage progenitor cells) have been shown to exert
therapeutic effects on cartilage tissue in experimental models. Bioscaffolds loaded with
therapeutic exosomes might be safer and more effective (due to the gradual release) than
repeated intra-articular injections. In the future, 3D printed scaffolds might also allow
the design of personalized and precision treatments [113]. Cellular senescence, which
burdens the OA phenotype, also represents an emerging opportunity for novel therapeutic
approaches through the exploitation of senolytics.
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